| [Objective] In order to study the relation between the concentration of plasma Middle Molecular Substance (MMS) in gravis hepatitis(especially chronic gravis hepatitis B) patients with development of the state of illness or the course of diseases; Besides, to examine the change about plasma MMS concentration in the patients complicating with hepatic encephalopathy (HE), spontaneous bacterial peritonitis(SBP), hepatorenal syndrome (HRS), respectively; to explore the relation between plasma Middle Molecular Substance (MMS) concentration and different prognosis groups; to analysize the correlation between plasma MMS concentration and some biochemical indices, such as: blood uria nitrogen, creatinine and so on; and to evaluate the removal effect about abnormally high MMS concentration of plasma in Artificial Liver Support System (ALSS) cases.[Methods] The method of ultraviolet spectrophotometer which adopt 5% trichloroacetic acid depositing plasma protein firstly, was introduced to detect plasma MMS concentration. There were 55 healthy donors in normalcontrol group. Devided by different prognosis, clinic improvement group and nonhealing group were formed; and compared plasma MMS concentration of one group with another; 89 gravis hepatitis patients were divided into No Complication group and Complication group by clinical character, then contrasted with normal control group about plasma MMS concentration. Furthermore, Complication group was subdivided into hepatic encephalopathy (HE) group, spontaneous bacterial peritonitis (SBP) group, hepatorenal syndrome(HRS)group by different types of complication, then also compared them with normal control group; In addition, according to the course of disease early or late, 74 chronic gravis hepatitis B cases were divided into Early Stage group, Middle Stage group, Late Stage group,respectively; and contrasted reciprocally. A relative dialysis was also performed between plasma MMS concentration and some biochemical indices in 89 gravis hepatitis patients. At last, we take a contrast between before therapy and after therapy in Artificial Liver Support System (ALSS) cases whose plasma MMS concentration was abnormally higher than normal control.[Results] (1) 55 healthy donors plasma MMS concentration is 338 ?70 u/dl. (2) The plasma MMS concentration of clinic improvement group (317 ?71u/dl, n=48) or nonhealing group (438 ?187 u/dl, n=41) was significantly different (P<0.01). (3) Among chronic gravis hepatitis No Complication group (326 ?81 u/dl, n=53) and Complication group (446 ?198u/dl, n=36), normal control group (338 ?70 u/dl, n=55), there was significantly different (P<0.01), including remarkably different (P<0.01) between No Complication group and Complication group, no difference between No Complication group andnormal control group (P>0.05). When hepatic encephalopathy (HE) group (381 ?58 u/dl, n=12), SBP group (426 ?190 u/dl, n=15), HRS group (648 ?270 u/dl, n=4) or mingled group (518 ?277u/dl, n=5) were contrasted with normal control group, it was significant (P<0.05), respectively. (4) Among Early Stage group (318 ?76 u/dl, n=23), Middle Stage group (365 ?140 u/dl, n=42) and Late Stage group (531 ?214 u/dl, n=9) of 74 chronic gravis hepatitis B, there was remarkably different(P <0.001); including Early Stage group versus Middle Stage group(P>0.05), Early Stage group versus Late Stage group(P<0.01), Middle Stage group versus Late Stage group(P<0.01).(5) It shows a positive correlation not only between plasma MMS concentration and blood BUN(r=0.605, p<0.01), but also between plasma MMS concentration and blood Cr (r=0.598, p<0.01) in 89 gravis hepatitis patients, and a negative relation with Total Bile Acid(TBA), but no relation with other biochemical indices, e.g. total protein(TP), albumen(ALB), globulin(GP), total bilirubin(TB), glutamate pyruvate transaminase(GPT), glutamicoxalo acetictransaminase(GOT), Prothrombin time(PT), respectively.(6) It shows no significantly different before therapy and aft...
|
PDF Full Text Request